Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Australasian Leukaemia and Lymphoma Group (ALLG) single arm phase II study to evaluate the efficacy of asciminib in newly diagnosed patients with chronic phase chronic myeloid leukaemia.

X
Trial Profile

An Australasian Leukaemia and Lymphoma Group (ALLG) single arm phase II study to evaluate the efficacy of asciminib in newly diagnosed patients with chronic phase chronic myeloid leukaemia.

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 24 Jan 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Asciminib (Primary) ; Dasatinib; Imatinib; Nilotinib
  • Indications Chronic myeloid leukaemia
  • Focus Therapeutic Use
  • Acronyms ALLG-CML13; Ascend-CML; CML13
  • Most Recent Events

    • 12 Dec 2023 Results(data cut-off in May 2023, n=101 )final analysis of Early Molecular Response and interim analysis of MMR by 12 months, presented at the 65th American Society of Hematology Annual Meeting and Exposition
    • 12 Dec 2023 Status changed from recruiting to active, no longer recruiting.
    • 13 Dec 2022 Interim Results(data cut-off July 15, 2022) assessing safety tolerability and efficacy of asciminib in the frontline setting presented at the 64th American Society of Hematology Annual Meeting and Exposition
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top